Contraception News and Research

Latest Contraception News and Research

Oregon scientist investigates safety, effectiveness of novel low-cost family-planning option

The Bill & Melinda Gates Foundation has awarded nationally prominent Oregon Health & Science University reproductive scientist Jeffrey T. Jensen, M.D., M.P.H., a $100,000 grant to investigate the safety and effectiveness of a novel low-cost family-planning option that may be applicable to women in low-resource countries worldwide.

15 Nov 2010

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

A vaginal gel that affords both contraception and HIV protection using nanoparticles that carry bee venom is one of the bold, unconventional ideas that won a 2010 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation.

10 Nov 2010

Health reform updates: Biotech grants, privacy issues and birth control coverage

Firms vying to tap the fund a $1 billion fund meant to catalyze research on new biologic treatments for cancer and other diseases may be disappointed in the outcome, The Washington Post reports. "[W]ith so many companies applying for a share of the money, many firms got much smaller allotments than requested and said the financial boost won't go as far as they had initially hoped.

8 Nov 2010

GOP claims Statehouse victories that could set back health law implementation

"The Democrats' ambitious health care overhaul is facing roadblocks from newly elected state officials who harshly criticized it while campaigning and who are now in a position to make good on their promises," Kaiser Health News reports. The GOP made significant political gains in Tuesday's election, taking "Governors' mansions in several states." Among the newly elected governors were Sam Brownback of Kansas, "who called the reform law 'an abomination,'" and Tennessee's Bill Haslam, who called the law "an 'intolerable expansion' of federal power."

4 Nov 2010

Today's Op-Eds: Birth control coverage, 'free' medical care, profitable nursing homes

For every extra benefit Congress has required health insurers to provide, there is an extra cost. Ultimately, we all will pay the cost of these "free" services in the form of lower wages, higher taxes or higher health insurance premiums.

3 Nov 2010

Health law challenges: Birth control, grandfathering, state's exchanges

The Associated Press: Among the complications posed by the health law is the fight over "social mores" that will could be triggered by the possibility that free contraception will be made available to women as a result of its provisions. A panel of experts set up by the Institute of Medicine will meet in November to determine what types of contraception should be considered "preventive care" under provisions barring insurers from charging copays for such services.

2 Nov 2010

First Edition: November 1, 2010

In today's health policy headlines, how will Tuesday's election impact the health law?

1 Nov 2010

Women with anorexia nervosa at risk of unplanned pregnancies and induced abortions

A new study by University of North Carolina at Chapel Hill and Norwegian researchers has found that women with anorexia nervosa are much more likely to have both unplanned pregnancies and induced abortions than women who don't have the serious eating disorder.

30 Oct 2010

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Agile Therapeutics announced results today from a Phase 2 clinical study of AG200-15, Agile's weekly contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG). According to the clinical findings, AG200-15 provides a low daily dose of estrogen equivalent to 30 micrograms EE, similar to that in low-dose, oral contraceptive (OC) pills.

26 Oct 2010

FDA approves LO LOESTRIN FE tablets for oral contraception

Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) for the prevention of pregnancy.

25 Oct 2010

U.N. reports explore issues facing women worldwide

Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.

22 Oct 2010

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Adamis Pharmaceuticals Corporation today announced the completion of the acquisition from Colby Pharmaceuticals of the remaining exclusive license agreements relating to two drug product candidates for the treatment of prostate cancer (PCa).

20 Oct 2010

Planned Parenthood launches campaign for free contraceptives as part of health law

NPR's Shots blog reports that the American Congress of Obstetricians and Gynecologists is joining Planned Parenthood on a campaign to allow free prescription contraceptives as part of the health reform law.

14 Oct 2010

Woman’s socioeconomic status impacts clinicians' decisions for contraception: Study

A woman's race/ethnicity and socioeconomic status impact whether health care providers recommend one of the most highly effective forms of contraception, a UCSF study confirms. The results also indicate that the interaction of both factors plays a role in clinicians' decisions.

12 Oct 2010

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA (tranexamic acid) tablets for cyclic heavy menstrual bleeding in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.

7 Oct 2010

Agile completes enrollment in AG200-15 Phase 3 contraceptive patch study

Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.

4 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Mandatory contraceptive policy in clinical trials is excessive and can safely be relaxed

Research ethics review committees often require all women of childbearing age who enroll in clinical trials to use contraceptives to protect against a developing fetus being exposed to potentially harmful drugs. A mandatory contraceptive policy is often imposed even when there is no evidence that a trial drug could harm a fetus or when women have no chance of becoming pregnancy. This requirement is excessive and can safely be relaxed in many cases, according to a report in IRB: Ethics & Human Research.

4 Oct 2010

HHS announces grants for teen pregnancy prevention programs

The U.S. Department of Health and Human Services (HHS) announced today that $155 million in teen pregnancy prevention grants are being awarded to states, non-profit organizations, school districts, universities, and others.

1 Oct 2010

Contraception News and Research

Latest Contraception News and Research

Oregon scientist investigates safety, effectiveness of novel low-cost family-planning option

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

Health reform updates: Biotech grants, privacy issues and birth control coverage

GOP claims Statehouse victories that could set back health law implementation

Today's Op-Eds: Birth control coverage, 'free' medical care, profitable nursing homes

Health law challenges: Birth control, grandfathering, state's exchanges

First Edition: November 1, 2010

Women with anorexia nervosa at risk of unplanned pregnancies and induced abortions

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

FDA approves LO LOESTRIN FE tablets for oral contraception

U.N. reports explore issues facing women worldwide

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Planned Parenthood launches campaign for free contraceptives as part of health law

Woman’s socioeconomic status impacts clinicians' decisions for contraception: Study

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Agile completes enrollment in AG200-15 Phase 3 contraceptive patch study

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Mandatory contraceptive policy in clinical trials is excessive and can safely be relaxed

HHS announces grants for teen pregnancy prevention programs

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Contraception News and Research

Latest Contraception News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in